发明名称 |
ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES |
摘要 |
<p>The present invention discloses and claims methods and compositions for the treatment of platinum and/or taxane cancer treating agent-resistanf-refractory sub-populations and/or the mucinous adenocarcinoma sub-type of ovarian cancer subjects with the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2'-trimethylsilyl) ethyl]-20(S) camptothecin). The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed.</p> |
申请公布号 |
WO2015023552(A1) |
申请公布日期 |
2015.02.19 |
申请号 |
WO2014US50464 |
申请日期 |
2014.08.10 |
申请人 |
BIONUMERIK PHARMACEUTICALS, INC. |
发明人 |
HAUSHEER, FREDERICK, H. |
分类号 |
A61P35/00 |
主分类号 |
A61P35/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|